Document Detail


Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study.
MedLine Citation:
PMID:  22427401     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: Echocardiographic contrast (EC) improves the diagnostic accuracy of suboptimal echocardiograms. In October 2007, the Food and Drug Administration (FDA) placed a black box warning on the label of the perflutren-based agents Definity and Optison, contraindicating their use in patients with pulmonary hypertension (PHT) and unstable cardiopulmonary status, after serious cardiopulmonary reactions occurred in temporal relation to EC administration. In 2008 and 2011, the FDA revised the black box warning allowing their use in this same population. However, limited data exist regarding the safety profile of these agents in patients with PHT.
METHODS AND RESULTS: Consecutive hospitalized patients with PHT who were referred for echocardiographic evaluation, but required the use of EC, were included. All our patients received the EC agent Definity. We evaluated these patients for serious adverse events (respiratory decompensation, hypotension, syncope, convulsions, arrhythmias, anaphylactic reactions, or death) occurring within 24 h of EC administration. The study group included 1513 patients (age 69 ± 14 years, 55% males, BMI 33 ± 9 kg/m(2)), of which 911 (60%) had mild PHT, 515 (34%) had moderate PHT, and 87 (6%) had severe PHT. The mean pulmonary artery systolic pressures (PASP) in the groups with mild, moderate, and severe PHT were 41 ± 4 (range 35-49) mmHg, 55 ± 5 (range 50-69) mmHg, and 78 ± 9 (range 70-122) mmHg, respectively. The incidence of adverse events in all subgroups was rare (0.002%) and they were not attributed to EC because of temporal and clinical considerations.
CONCLUSION: The use of the EC agent Definity is safe in hospitalized patients with PHT.
Authors:
Omar Wever-Pinzon; Valentin Suma; Ameeta Ahuja; Jorge Romero; Nishtha Sareen; Sonia A Henry; Maria De Benedetti Zunino; Farhan F Chaudhry; Ramya S Suryadevara; Mark V Sherrid; Farooq A Chaudhry
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't     Date:  2012-03-16
Journal Detail:
Title:  European heart journal cardiovascular Imaging     Volume:  13     ISSN:  2047-2412     ISO Abbreviation:  Eur Heart J Cardiovasc Imaging     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-09-18     Completed Date:  2013-02-18     Revised Date:  2014-01-31    
Medline Journal Info:
Nlm Unique ID:  101573788     Medline TA:  Eur Heart J Cardiovasc Imaging     Country:  England    
Other Details:
Languages:  eng     Pagination:  857-62     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Contrast Media / adverse effects*
Echocardiography*
Female
Fluorocarbons
Hospitalization*
Humans
Hypertension, Pulmonary / pathology,  ultrasonography*
Iatrogenic Disease
Male
Patient Care*
Retrospective Studies
Safety*
Grant Support
ID/Acronym/Agency:
T32 HL007576/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Contrast Media; 0/Fluorocarbons; 76-19-7/perflutren
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of residual regurgitation after aortic valve replacement.
Next Document:  Two-dimensional speckle tracking of the left ventricle in patients with systemic sclerosis for an ea...